

Resource Summary Report

Generated by [kravitz2](#) on Aug 14, 2026

MedChemExpress

RRID:SCR_025062

Type: Tool

Proper Citation

MedChemExpress (RRID:SCR_025062)

Resource Information

URL: <https://www.medchemexpress.com/about-us.htm>

Proper Citation: MedChemExpress (RRID:SCR_025062)

Description: Company offers research chemicals and biochemicals for scientific use. Provides customer oriented services including customized order volume ranging from milligrams to kilograms scale, structurally and synthetically diverse biologically active compounds.

Resource Type: commercial organization

Keywords: research chemicals, biochemicals, customer oriented services, customized order volume, biologically active compounds,

Resource Name: MedChemExpress

Resource ID: SCR_025062

Record Creation Time: 20240305T200904+0000

Record Last Update: 20260808T190718+0000

Ratings and Alerts

No rating or validation information has been found for MedChemExpress.

No alerts have been found for MedChemExpress.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 13 mentions in open access literature.

Listed below are recent publications. The full list is available at [kravitz2](#) .

Gulla S, et al. (2026) MECOM Function Is Critical for AR-Driven Treatment-Resistant Prostate Cancer. *Cancer research*, 86(9), 2143.

Thielen N, et al. (2026) High-throughput screening identifies NT-1 that synergizes with MRTX1133 against acquired resistant KRASG12D colorectal cancer. *NPJ precision oncology*, 10(1).

Ziegler Y, et al. (2026) JAK/STAT1-interferon-ISGylation networks in breast cancer resistance to inhibitors of FOXM1 and CDK4/6. *NPJ breast cancer*, 12(1).

Yapindi L, et al. (2026) Dual Inhibition of TRIP13 and Aurora A Induces Mitotic DNA Damage and Concurrent Pyroptotic-Apoptotic Cell Death in Rb-Deficient Cancer Cells. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(14), 3043.

Li C, et al. (2026) ARID1A deficiency unleashes centromeric RNA transcription to drive chromosomal instability and boosts PKMYT1 inhibitor efficacy via RNA sensing. *bioRxiv : the preprint server for biology*.

Sandoval TA, et al. (2026) Chemoradiation Reprograms Tumor Cells and the Immune Microenvironment in Cervical Cancer. *Cancer research*, 86(7), 1639.

Banerjee M, et al. (2026) FASN Inhibition Enhances the Efficacy of Chemotherapy in Colorectal Cancer by Inhibiting the DNA Damage Response. *Cancer research*, 86(10), 2522.

Boudjadi S, et al. (2026) Involvement of the FGF8/FGF Receptor Signaling Pathway in the Maintenance and Progression of Fusion-Positive Rhabdomyosarcoma. *Molecular cancer therapeutics*, 25(3), 493.

Wang Y, et al. (2025) Homeodomain protein PRRX1 anchors the Ku heterodimers at DNA double-strand breaks to promote nonhomologous end-joining. *Nucleic acids research*, 53(6).

Thielen N, et al. (2025) High Throughput Screening Identifies Small Molecules that Synergize with MRTX1133 Against Acquired Resistant KRAS G12D Mutated CRC. *bioRxiv : the preprint server for biology*.

Yang L, et al. (2024) Neurons enhance blood-brain barrier function via upregulating claudin-5 and VE-cadherin expression due to glial cell line-derived neurotrophic factor secretion. *eLife*, 13.

Abusdal M, et al. (2024) PCSK1N as a tumor size marker and an ER stress response protein in corticotroph pituitary adenomas. *The Journal of clinical endocrinology and metabolism*.

Gao S, et al. (2022) Deep learning applications for the accurate identification of low-transcriptional activity drugs and their mechanism of actions. *Pharmacological research*,

180, 106225.